Understand the source comparison
Best Peptides to Get Rid of Love Handles Ranked: Evidence-Based Comparison
Before selecting a peptide protocol, understand that subcutaneous fat loss depends on sustained caloric deficit. Peptides enhance the process but don't replace it. The table below ranks compounds by clinical evidence for total body fat reduction, mechanism of
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide protocol, understand that subcutaneous fat loss depends on sustained caloric deficit. Peptides enhance the process but don't replace it. The table below ranks compounds by clinical evidence for total body fat reduction, mechanism of action, and typical timelines for visible flank fat changes.
- Tirzepatide (15mg weekly)
- Dual GIP/GLP-1 agonist. Slows gastric emptying, enhances insulin sensitivity, increases energy expenditure
- 20–22% total body weight over 72 weeks (SURMOUNT-1)
- Visible reduction at 12–16 weeks, maximal effect at 20+ weeks
- Most effective option for stubborn subcutaneous fat. Dual-receptor action produces greater total fat loss than GLP-1 monotherapy
- Semaglutide (2.4mg weekly)
- GLP-1 receptor agonist. Extends satiety, reduces ghrelin rebound, improves glucose handling
- 14.9% total body weight over 68 weeks (STEP-1)
- Visible reduction at 16–20 weeks, preferential visceral loss early
- Strong second choice. Slightly less subcutaneous fat mobilisation than tirzepatide but well-documented safety profile
- CJC-1295 + Ipamorelin (daily dosing)
- GH secretagogues. Increase lipolytic enzyme activity, enhance fat oxidation during fasted states
- 3–5% fat mass reduction over 12 weeks (requires concurrent deficit)
- Modest flank changes at 16+ weeks with strict nutrition adherence
- Limited as monotherapy for love handles. Best as adjunct to GLP-1 protocols or for patients maintaining low body fat
- Tesofensine (1mg daily)
- Triple monoamine reuptake inhibitor. Suppresses appetite, increases thermogenesis
- 12.8% body weight over 24 weeks (Phase 3 trial)
- Visible reduction at 12–14 weeks
- Potent appetite suppression with minimal GI side effects. Regulatory approval pending, limited availability
- MK-677 (25mg daily)
- Ghrelin mimetic. Stimulates GH/IGF-1 secretion, preserves lean mass during deficit
- 0.45kg fat mass reduction over 8 weeks (modest effect)
- Minimal direct flank fat loss. Value is lean mass preservation
- Adjunct only. Oral administration convenient but fat loss effect insufficient as standalone therapy